Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and ...
The Healthy @Reader's Digest on MSN
What I wish I’d known about cataract surgery: A doctor details what patients should know about a common procedure
What are the signs that show I need cataract surgery? “There are several key signs that someone may need cataract surgery,” ...
Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...
Our product picks are editor-tested, expert-approved. We may earn a commission through links on our site. Why Trust Us? Whether you're a freerider, a weekend resort warrior, or a cross-country lover, ...
After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration. After a cautious ...
We sat down with Schmid to discuss spinouts, robots, M&A strategy and how to grow the world’s second-largest device business faster. Major medtech companies like BD, Edwards Lifesciences, Medtronic ...
Bausch + Lomb intraocular lenses have been recalled due to reports of toxic anterior segment syndrome (TASS), a severe inflammatory eye reaction that can cause lasting damage. Those affected may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback